Expert: Oral At-Home Pill May Change the Game for COVID-19 Treatment


Michael Frank, CEO of Revive Therapeutics, discussed the results of a phase 3 trial investigating bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

Pharmacy Times interviewed Michael Frank, CEO of Revive Therapeutics, on a phase 3 trial investigating the use of bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

During the discussion, Frank addressed why bucillamine was investigated as a potential treatment for COVID-19; whether bucillamine is already FDA-approved for other treatment targets; which COVID-19 symptoms bucillamine has shown the potential to treat; how bucillamine is unique as a treatment for COVID-19 symptoms; what the timeline for a potential FDA approval of bucillamine may be; whether the FDA has fast-tracked bucillamine’s expanded approval in a fashion similar to other COVID-19 treatments; and how bucillamine could change the landscape for the currently available COVID-19 treatments.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.